Lixte Biotechnology Holdings, Inc. (LIXT)

LIXT Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1.04	4.2	5.35	4.82	5.07
Cash & Short-Term Investments	1.04	4.2	5.35	4.82	5.07
Cash Growth	-75.28%	-21.48%	10.98%	-4.84%	95.06%
Prepaid Expenses	0.11	0.03	0.06	0.12	0.08
Other Current Assets	-	0.08	0.15	0.15	0.08
Total Current Assets	1.15	4.31	5.56	5.09	5.23
Total Assets	1.15	4.31	5.56	5.09	5.23
Accounts Payable	0.06	0.12	0.18	0.19	0.19
Accrued Expenses	0.03	0.04	0.05	0.03	-
Other Current Liabilities	0.24	0.16	0.17	0.08	0.03
Total Current Liabilities	0.32	0.31	0.4	0.3	0.22
Total Liabilities	0.32	0.31	0.4	0.3	0.22
Common Stock	0	0	0	0	0
Additional Paid-In Capital	49.39	48.98	45.06	38.37	31.86
Retained Earnings	-52.07	-48.48	-43.39	-37.08	-30.35
Total Common Equity	-2.67	0.49	1.67	1.29	1.51
Shareholders' Equity	0.83	3.99	5.17	4.79	5.01
Total Liabilities & Equity	1.15	4.31	5.56	5.09	5.23
Net Cash (Debt)	1.04	4.2	5.35	4.82	5.07
Net Cash Growth	-75.28%	-21.48%	10.98%	-4.84%	95.06%
Net Cash Per Share	0.46	2.19	3.38	3.58	4.50
Filing Date Shares Outstanding	2.68	2.25	1.67	1.37	1.35
Total Common Shares Outstanding	2.25	2.25	1.66	1.37	1.24
Working Capital	0.83	3.99	5.17	4.79	5.01
Book Value Per Share	-1.19	0.22	1.00	0.94	1.22
Tangible Book Value	-2.67	0.49	1.67	1.29	1.51
Tangible Book Value Per Share	-1.19	0.22	1.00	0.94	1.22

Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q